Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jussi Sutinen

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Current Opinion in Infectious Diseases|January 14, 2005
Interventions for managing antiretroviral therapy-associated lipoatrophyJussi Sutinen
Duodecim; Laaketieteellinen Aikakauskirja|June 24, 2011
[When should a patient be tested for HIV?]Jussi Sutinen
PPAR Research|December 20, 2008
The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patientsJussi Sutinen
Duodecim; Laaketieteellinen Aikakauskirja|February 9, 2012
[HIV--from a lethal disease to a chronic illness]Jussi Sutinen, Matti Ristola
Lancet (London, England)|February 14, 2004
Managing HIV lipoatrophyGraeme Moyle, Jussi Sutinen
American Journal of Physiology. Endocrinology and Metabolism|October 26, 2006
Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophyJussi Sutinen, Hannele Yki-Järvinen
Duodecim; Laaketieteellinen Aikakauskirja|December 1, 2017
HIV infection and cancerJussi Sutinen, Sirpa Leppä, Maija Tarkkanen
AIDS Patient Care and Stds|November 20, 2019
Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World SettingKai Juhani Kauppinen, Pia Kivelä, Jussi Sutinen
AIDS (London, England)|June 21, 2022
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gainKai Juhani Kauppinen, Inka Aho, Jussi Sutinen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2019
Reply to Krahn and SebastianiHannele Yki-Järvinen, Susanna Lallukka-Brück, Jussi Sutinen
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Opinion in Infectious Diseases|January 14, 2005
Interventions for managing antiretroviral therapy-associated lipoatrophyJussi Sutinen
Duodecim; Laaketieteellinen Aikakauskirja|June 24, 2011
[When should a patient be tested for HIV?]Jussi Sutinen
PPAR Research|December 20, 2008
The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patientsJussi Sutinen
Duodecim; Laaketieteellinen Aikakauskirja|February 9, 2012
[HIV--from a lethal disease to a chronic illness]Jussi Sutinen, Matti Ristola
Lancet (London, England)|February 14, 2004
Managing HIV lipoatrophyGraeme Moyle, Jussi Sutinen
American Journal of Physiology. Endocrinology and Metabolism|October 26, 2006
Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophyJussi Sutinen, Hannele Yki-Järvinen
Duodecim; Laaketieteellinen Aikakauskirja|December 1, 2017
HIV infection and cancerJussi Sutinen, Sirpa Leppä, Maija Tarkkanen
AIDS Patient Care and Stds|November 20, 2019
Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World SettingKai Juhani Kauppinen, Pia Kivelä, Jussi Sutinen
AIDS (London, England)|June 21, 2022
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gainKai Juhani Kauppinen, Inka Aho, Jussi Sutinen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2019
Reply to Krahn and SebastianiHannele Yki-Järvinen, Susanna Lallukka-Brück, Jussi Sutinen
Pageof 5